We refuse to give up. Ever.

Komen has led the fight against breast cancer for more than three decades. Fighting for cures in laboratories. And fighting for women and men everywhere. We’ve transformed how the world treats and talks about this disease and have helped turn millions of breast cancer patients into breast cancer survivors.

A Promise Renewed

Inside Komen: April 1, 2014 – March 31, 2015

Letter from Judy Salerno:  A Mission Ignited ......................................................... 2
Mission – Research:  Moving Science Forward with Passion, Precision and Purpose ........ 4
Mission – Advocacy:  For Those We’ve Lost and Those We Can Protect ............................ 6
Mission – Community Health:  Making a Difference Where We Live .............................. 8
Mission – Global Impact  Transcending Borders, Beliefs and Languages ............................ 10
Fundraising and Stewardship:  Maximizing Our Collective Impact .................................. 12
Consolidated Statement of Financial Position ................................................................. 14
Komen Scientific Advisory Board .................................................................................. 15
Komen Scholars .............................................................................................................. 16
A Mission Ignited

To Our Komen Family,

In 2014, my first full year as president and CEO of Susan G. Komen, I witnessed the power of the Komen Promise in action. More importantly, I saw the need to strengthen that Promise with fresh approaches: with targeted programs to reduce breast cancer deaths by working for health equity, an increased focus on metastatic breast cancer and ensuring the future of breast cancer research through support for scientists just starting their careers.

This is our Promise Renewed.

We have had much to be thankful for in our first 32 years. The work of Susan G. Komen and others has helped reduce breast cancer death rates by more than a third since 1989 in developed countries. Decades of research—much of it funded by Komen—unlocked the secrets of this family of diseases that comprise breast cancer and set the stage for better therapies for the disease. Thanks to that research and to community health programs, many women and men today are living longer, with more knowledge and more options for treatment than at any time in our history. And from a time of silence and shame around breast cancer, Komen sparked a global community, millions strong, proud, united and vocal in their determination to end this disease.

Years of experience in cancer research, public health and global advocacy have taught us that organizations like Komen have no time to rest on laurels or to celebrate the status quo. Breast cancer remains a cunning killer. It continues to claim 40,000 lives a year in the U.S. and is taking an increasing toll in developing countries. This means that we must be more targeted, and smarter, to loosen breast cancer’s grip on the women and men we love and reduce both mortality and incidence of this disease.

In our Fiscal Year 2015, that meant identifying the toughest issues that remain, and setting strategies to overcome them. These include:

- **Achieving Health Equity**: African-American women die of breast cancer at rates 40 percent or higher than white women in the U.S. Access to quality health care for all is a critical component in reducing breast cancer death rates among these women and for all of the medically underserved. To that end, we have launched a national health equity initiative to ensure that no person dies of breast cancer for lack of access to care.

- **Taking on the Toughest Forms of Breast Cancer**: Metastatic breast cancer kills most of the 40,000 women and men who die of breast cancer each year. Nearly half of Komen’s new research funding in FY15 was focused on metastatic breast cancer. We have invested $147 million in research focused on metastatic breast cancer since our founding, more than any other nonprofit, and built new partnerships to address the specific needs of these patients.

- **Ensuring the Next Generation of Breast Cancer Research**: Stagnation in federal cancer research funding is forcing promising young scientists out of breast cancer research and into other fields. We must keep the pipeline of new ideas open and flowing, and to that end, Komen committed nearly half of our research funding this year to young investigators, with a pledge to do so again in 2016, while also funding established scientists and clinicians.

- **Helping where Help is Needed Most**: We looked inward, and strengthened our internal operating systems and structures so that our network of more than 100 Komen Affiliates can continue to be the face, hands and heart of Komen in our communities. Our grassroots network of Affiliates sets us apart from other breast cancer organizations. It served hundreds of thousands of women last year, and the strengthening of our network enhances our ability to serve people who need us for years to come.

We are able to focus our mission and grow our impact, through the support of our donors, partners and friends. And despite economic challenges in the U.S. and abroad, we have carefully stewarded those donations to ensure that on average this fiscal year at least 80 percent of every dollar we spend goes directly to our mission programs.

In the pages that follow, we share the stories and impact of this Komen Promise in action. More importantly, I saw the need to strengthen that Promise with fresh approaches.

Dr. Judy Salerno, Komen staff, members of the Komen Scientific Advisory Board and Komen Scholars, leading scientists from around the world meet in Beijing. (See page 11)
Moving Science Forward with Passion, Precision and Purpose

For more than 30 years, our renowned research program, guided by leading experts and passionate advocates, has helped push our understanding of breast cancer forward. With more than $889 million invested in breast cancer research to date, we are gaining on breast cancer every day. Through our comprehensive approach and commitment to funding early-career investigators, we are ensuring that momentum in breast cancer research, which has saved so many lives, continues.

• Komen-funded research confirmed four subgroups of HER2+ breast cancer with different molecular characteristics which can be used to personalize treatment.

• Landmark report from Metastatic Breast Cancer Alliance (Komen is a founding member) found MBC research to be underfunded and identified opportunities to close gaps in understanding MBC and support for people living with MBC.

• Komen partnered with the Dr. Susan Love Foundation to fund $50K in pilot grants to researchers using next-generation technology to study the fundamental question, “How does breast cancer develop?”

FY15 Highlights

• Komen awarded $1.1M to the Komen Tissue Bank (KTB) at the IU Simon Cancer Center, the only repository in the world for normal breast tissue and matched serum, plasma and DNA. More than 4,000 healthy women have donated tissue and approximately 10,000 have donated blood to the KTB, which is accelerating research into the causes and prevention of breast cancer.

• Komen provided $3.75M in support to the Translational Breast Cancer Research Consortium (TBCRC), a collaborative network of investigators from 17 U.S. medical centers focused on conducting innovative clinical trials for breast cancer. Since 2006, TBCRC has enrolled more than 3000 patients in 30 clinical trials.

• Komen-funded research confirmed four subgroups of HER2+ breast cancer with different molecular characteristics which can be used to personalize treatment.

2015 Research Grants Awarded:
• 35% Treatment
• 25% Cancer Control, Survivorship and Outcomes
• 22% Biology
• 12% Early Detection, Diagnosis and Prognosis
• 6% Causes of Breast Cancer
• Additionally, nine grants to global and community health research programs

2015 Research Grants

Komen grants addressing the most challenging areas in breast cancer research, including:
• 36 in Metastasis
• 19 in Triple Negative
• 18 in Drug Resistance
• 15 in Health Inequities
• 13 in Novel Therapies
Patients and their physicians should be free to make treatment decisions based on what is best for that patient rather than on financial considerations. And this legislation will ensure cancer patients receive fair and equal access to both oral and IV anti-cancer medication.”

– Komen South Dakota Executive Director Mary Kolsrud, on the signing into law of Senate Bill 101

We believe that Komen—as a patient advocacy organization with first-hand knowledge of how breast cancer touches local communities—must engage policymakers and government as partners in our efforts to end breast cancer.

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

FY15 Highlights

- Komen, Young Survival Coalition and Living Beyond Breast Cancer supported the reauthorization of the Education and Awareness Requires Learning Young (EARLY) Act.
- Komen supported the Patients’ Access to Treatments Act.
- The seven Susan G. Komen Affiliates in California joined together to announce an intensive, two-year, statewide initiative focusing on African-American women’s breast health.

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.

Our Advocacy Impact

For Those We’ve Lost and Those We Can Protect

More than 230,000 cases of breast cancer will be diagnosed in the U.S. in 2015. Each of those women and men, along with their families and friends, and the more than 3 million breast cancer survivors in the U.S. today, have concerns about timely access to quality care, getting the best treatment and what the future holds. For more than 30 years, Komen has worked to make sure their voices are heard, fighting for access to affordable, high-quality breast health and cancer care services and ensure that federal research funding remains a priority.
Our Community Health Impact

Making a Difference Where We Live

Ending breast cancer requires more than research: it also requires an investment in people and resources that can help women and men today. Providing insurance co-pays for low-income women and men; medical supplies for those who are financially stretched; patient navigation programs to help women and men through the health care system; help with rent payments and groceries for those whose cancer has created a medical and financial crisis. Sometimes, a person facing breast cancer just needs a knowledgeable friend who can listen and assist. That’s where Komen comes in.

Last year, Komen helped more than 30,000 women and men with the financial, emotional and social issues that accompany a breast cancer diagnosis. Komen paid for screenings for more than 300,000 women and men who wouldn’t otherwise be able to afford them. Komen Affiliates were out in communities nationwide, educating women about the signs and symptoms of breast cancer, how to reduce their risk, and what to expect once a diagnosis is made. Komen’s website made breast cancer information accessible to millions.

“‘When I had no way to help myself, Komen’s door opened for me and saved my life.’”
– Ruth, age 33, breast cancer survivor (courtesy Komen Orange County)

FY15 Highlights – Education

• With more than 7 million page views in the About Breast Cancer section alone, people received the breast health information they needed from Komen’s website – komen.org – which launched a new design in 2014.
• In communities from Washington, D.C. to Honolulu, Komen advocates reached out to women of color, uninsured and medically vulnerable women—who are at the greatest risk for late-stage diagnosis—to educate and offer assistance.
• Through the generous support of Walgreens and its customers, Komen has provided funding to 26 Komen Affiliates (totaling more than $1.5 million) to develop and deploy breast health and breast cancer programs in their service areas.
• Komen’s toll-free national Breast Care Helpline connected more than 14,000 callers with vital breast health information, support and resources.

FY15 Highlights – Screening

• Last year, more than 300,000 women and men received a free or reduced-cost breast screening through Komen programs.
• Komen awarded nearly $400,000 for two new community grants to reach low-income, minority and uninsured women who fall through the health care gaps in the Washington, D.C. metro area, where death rates from breast cancer continue to rank above national averages.

FY15 Highlights – Treatment

• Komen funded patient navigation programs in 16 communities, giving women knowledgeable resources to guide them through the health care system.
• With partners at CancerCare and the Patient Advocate Foundation, Komen made it possible for nearly 20,000 people to receive financial, medical and/or psychosocial support. Komen has funded more than $13 million to these programs over the past 7 years.
Transcending Borders, Beliefs and Languages

Breast cancer is the most common women’s cancer in the world — and growing in countries least able to deal with it. In just three decades, the number of new breast cancer cases has doubled, with the highest increases seen throughout North and Western sub-Saharan Africa, the Middle East, Southeast Asia and Central Latin America. Further, breast cancer remains the leading cause of cancer death in women in low-resource countries around the world. We believe that where a woman lives should not determine whether she lives. So we’re fighting breast cancer in every corner of the world — in partnership with government agencies, non-governmental organizations (NGOs) and corporate partners. Together we’re providing health systems assessments, education, early detection and treatment programs in our efforts to save lives and reduce the devastation of breast cancer.

Our Global Impact

In just three decades, the number of new breast cancer cases has doubled worldwide, with the highest increases seen throughout North and Western sub-Saharan Africa, the Middle East, Southeast Asia and Central America.

FY15 Highlights – Global Impact

- In partnership with the Caterpillar Foundation, Komen funded programs in Brazil, Panama and Mexico that have, since 2011, trained 2,500 community health workers and medical providers, and reached more than 50,000 community members through breast self-awareness and breast cancer educational workshops.

- Through F15, Komen, in partnership with GE Healthymagination, has launched programs in China and Saudi Arabia to develop culturally appropriate breast health education materials, educate community members, train medical providers, and support breast health and breast cancer education events.

- In Africa, Komen-funded programs and partnerships helped thousands of women facing breast cancer in regions where resources are scarce. Komen funded the establishment of two breast cancer clinics in Zambia, and supported screening of 6,200 women as a founding member of the Pink Ribbon Red Ribbon partnership, affiliated with the George W. Bush Institute and government/non-government organizations.
Fundraising and Stewardship

Maximizing Our Collective Impact

Our work would not be possible without the generous support of donors, partners, Race participants, 3-Day walkers and every person who baked, bowled, crafted, flew and went above and beyond to advance our vision of a world without breast cancer. Our fight is their fight, and together, we are making an impact in the lives of women and men facing breast cancer today, and investing in a future where no one fears the words, “you have breast cancer.”

Fueling that mission is a culture of transparency and stewardship. We are focused on the task at hand, and proud to report that, for the 11th year in a row, on average at least 80 cents of every dollar was invested in mission programs.

FY15 Highlights

- The Race for the Cure® series raised $86.4 million with 154 Races around the globe.
- New Balance became the T-shirt sponsor of Race for the Cure and also committed to continuing their sponsorship of Race and the Lace Up for the Cure CRM program through 2018.
- Walgreens customers raised $3.5M through the at-register program, helping to fund breast cancer programs in 16 communities, as well as the Treatment Assistance Program and the Komen helpline.
- Ballantyne Rally (largest Rally for the Cure event in the country) continued their incredible success by raising nearly $200,000 in Charlotte, NC.
- Komen and WWE teamed up for National Women’s Health Week to make women’s health a priority.

“One in eight women in the U.S. is diagnosed with breast cancer in her lifetime. That’s an incredibly scary statistic. In my family, we have been touched twice. However, this is not about me. This is about the more than 3 million breast cancer survivors in the U.S. today, and the fact that this is still the second leading cause of cancer-related death among women in the U.S.”

– Pippa Mann, IndyCar driver and Komen partner
As of March 31, 2014                2015

**Assets:**
- Cash and cash equivalents  109,297,704  154,493,674
- Investments  248,921,096  150,955,835
- Receivables  43,879,176  39,969,851
- Prepaid expense and other assets  2,244,790  3,867,213
- Property and equipment, net  1,290,816  2,798,585
- Total Assets  405,633,582  352,085,158

**Liabilities:**
- Accounts payable, accrued expenses, and other payables  9,047,813  7,806,906
- Deferred revenue and rent  3,126,043  2,560,573
- Grants payable, net  197,635,702  164,476,949
- Total Liabilities  209,809,558  174,844,428

**Net Assets:**
- Unrestricted - undesignated  134,678,879  119,868,140
- Unrestricted - board designated  1,000,000  1,000,000
- Total unrestricted  135,678,879  120,868,140
- Temporarily restricted  59,820,145  56,047,590
- Permanently restricted  325,000  325,000
- Total Net Assets  195,824,024  177,240,730

Total Liabilities and Net Assets  405,633,582  352,085,158

**Consolidated Statement of Financial Position**

<table>
<thead>
<tr>
<th>Public support and revenue:</th>
<th>Fiscal Year Ended March 31, 2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>112,818,654</td>
<td>117,880,939</td>
</tr>
<tr>
<td>Komen Race for the Cure &amp; Breast Cancer 3 Day</td>
<td>180,440,371</td>
<td>149,489,011</td>
</tr>
<tr>
<td>Less: Direct benefit to donors and sponsors</td>
<td>(27,396,500)</td>
<td>(25,130,890)</td>
</tr>
<tr>
<td>Net Public Support</td>
<td>265,862,525</td>
<td>242,239,060</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Revenue:</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investment Income</td>
<td>21,009,967</td>
<td>7,521,315</td>
</tr>
<tr>
<td>Other Income</td>
<td>436,777</td>
<td>915,987</td>
</tr>
<tr>
<td>Total Revenue</td>
<td>21,446,744</td>
<td>8,037,302</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total Net Public Support and Revenue:</th>
<th>Fiscal Year Ended March 31, 2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>287,409,269</td>
<td>250,276,362</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses:</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td>217,779,902</td>
<td>216,147,708</td>
</tr>
<tr>
<td>Management and General</td>
<td>23,258,997</td>
<td>20,719,400</td>
</tr>
<tr>
<td>Fundraising</td>
<td>36,988,727</td>
<td>31,992,548</td>
</tr>
<tr>
<td>Total Expenses</td>
<td>278,027,626</td>
<td>268,859,656</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change in net assets</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Assets, beginning of year</td>
<td>186,442,381</td>
<td>195,824,024</td>
</tr>
<tr>
<td>Net assets end of year</td>
<td>195,824,024</td>
<td>177,240,730</td>
</tr>
</tbody>
</table>

**Consolidated Statement of Activities**

**Scientific Advisory Board**

The Scientific Advisory Board (SAB) provides strategic guidance and direction for our research and scientific programs, and plays a key role in guiding and prioritizing Komen’s global research investment. The SAB is led by the chief scientific advisors and serves as the executive committee of the Komen Scholars.

**Scientific Advisory Board**

George Sledge, Jr., M.D., Chief Scientific Advisor  
Stanford University School of Medicine  
Stanford, CA

Eric Winer, M.D., Chief Scientific Advisor  
Dana-Farber Cancer Institute  
Boston, MA

Carlos Arteaga, M.D.  
Vanderbilt-Ingram Cancer Center  
Nashville, TN

Myles Brown, M.D.  
Dana-Farber Cancer Institute  
Boston, MA

Powel Brown, M.D., Ph.D.  
The University of Texas Health Science Center at San Antonio  
San Antonio, TX

Karen Gelmon, M.D., F.R.C.P.C.  
British Columbia Cancer Agency  
Vancouver, Canada

Cheryl Jernigan, C.P.A., F.A.C.H.E.  
Advocate in Science  
Komen Greater Kansas City Affiliate  
Kansas City, MO

Amelie Ramirez, Dr. P.H.  
The University of Texas Health Science Center at San Antonio  
San Antonio, TX
Komen Scholars

The Komen Scholars are an advisory group of 60 distinguished leaders in breast cancer research and advocacy. Representing more than 32 institutions in seven countries, their expertise spans everything from clinical research and laboratory research to pathology, prevention, radiation oncology, surgery and other disciplines and specialties. They contribute to our programs, activities and events in many ways—most notably by leading and participating as reviewers in our scientific peer review process—and act as our ambassadors in communities around the U.S. and the world.

Several of the Komen Scholars are Advocates in Science — patient advocates who ensure that the unique perspectives of those affected by breast cancer are fully integrated into decisions at every step of the research process.

Komen Scholars

Benjamin Anderson, M.D.
University of Washington School of Medicine
Seattle, WA

Alan Ashworth Ph.D., F.R.S.
Institute of Cancer Research
London, England

Suni Badve, M.D., F.R.C.Path.
Indiana University Cancer Center
Indianapolis, IN

Kimberly Blackwell, M.D.
Duke University School of Medicine
Durham, NC

Gerard Blobe, M.D., Ph.D.
Duke University School of Medicine
Durham, NC

Melissa Bondy, Ph.D.
Baylor College of Medicine
Houston, TX

Joe Gray, Ph.D.
Oregon Health and Science University
Portland, Oregon

Nora Díaz, M.D.
The University of Washington Medical School
Seattle, WA

Susan Domchek, M.D.
The University of Pennsylvania School of Medicine
Philadelphia, PA

Karen Durham
Advocate in Science
Komen Tyler Affiliate
Tyler, TX

Matthew Ellis, M.B., B.Chir, Ph.D.
Baylor College of Medicine
Houston, TX

Carol Fabian, M.D.
University of Kansas Medical Center
Westwood, KS

Sandra Finestone, Psy.D.
Advocate in Science
Ireland Empire and Orange County Affiliates
Costa Mesa, CA

William Foulkes, M.B.B.S., Ph.D.
McGill University
Montreal, Canada

Patricia Ganz, M.D.
University of California, Los Angeles
Los Angeles, CA

Judy Garber, M.D., M.P.H.
Dana-Farber Cancer Institute
Boston, MA

Julie Gralow, M.D.
University of Washington School of Medicine
Seattle, WA

Joe Gray, Ph.D.
Oregon Health and Science University
Portland, Oregon

Theresa Guise, M.D.
Indiana University School of Medicine
Indianapolis, IN

Susan Hankinson, R.N., M.P.H, Sc.D.
The University of Massachusetts, Amherst
Amherst, MA

Daniel Hayes, M.D.
The University of Michigan Comprehensive Cancer Center
Ann Arbor, MI

Mig-Chie Hung, Ph.D.
The University of Texas M.D. Anderson Cancer Center
Houston, TX

Nola Hylton, Ph.D.
University of California, San Francisco
San Francisco, CA

Funda Meric-Bernstam, M.D.
The University of Texas M.D. Anderson Cancer Center
Houston, TX

Joe Gray, Ph.D.
Oregon Health and Science University
Portland, Oregon

Patricia Spears
Advocate in Science
Komen NC Triangle to the Coast Affiliate
Morrisville, NC

Komen Scholars cont.

Peggy Johnson
Advocate in Science
Komen Kansas Affiliate
Wichita, KS

V. Craig Jordan, OBE, Ph.D., D.Sc., F.Med.Sci.
The University of Texas M.D. Anderson Cancer Center
Houston, TX

Bella Kaufman, M.D.
Chaim Sheba Medical Center
Ramat Gan, Israel

Mary-Claire King, Ph.D.
University of Washington
Seattle, WA

Ian Krop, M.D., Ph.D.
Dana-Farber Cancer Institute
Boston, MA

Adrian Lee, Ph.D.
University of Pittsburgh Cancer Institute
Pittsburgh, PA

David Livingston, M.D.
Dana-Farber Cancer Institute
Boston, MA

David Mankoff, M.D., Ph.D.
The University of Pennsylvania School of Medicine
Philadelphia, PA

Funda Meric-Bernstam, M.D.
The University of Texas M.D. Anderson Cancer Center
Houston, TX

Nora Disis, M.D.
The University of Washington Medical School
Seattle, WA

Harikrishna Nakshatri, B.V.Sc., Ph.D.
Indiana University Simon Cancer Center
Indianapolis, IN

Olufunmilayo Olopade, M.D.
University of Chicago Medical Center
Chicago, IL

Bert O’Malley, M.D.
Baylor College of Medicine
Houston, TX

Ramón Parsons, M.D., Ph.D.
Mount Sinai School of Medicine
New York, NY

Ann Partridge, M.D., M.P.H
Dana-Farber Cancer Institute
Boston, MA

Rena Passick, Dr. P.H.
University of California, San Francisco
San Francisco, CA

Lori Pierce, M.D.
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI

Jennifer Pietenpol, Ph.D.
Vanderbilt-Ingram Cancer Center
Nashville, TN

Jeffrey Rosen, Ph.D.
Baylor College of Medicine
Houston, TX

Kathy Miller, M.D.
Indiana University Simon Cancer Center
Indianapolis, IN

Vered Steams, M.D.
Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

W. Fraser Symmans, M.D.
The University of Texas M.D. Anderson Cancer Center
Houston, TX

Geoffrey Wahl, Ph.D.
The Salk Institute for Biological Studies
La Jolla, CA

Danny Welch, Ph.D.
University of Kansas Cancer Center
Kansas City, KS

Julia White, M.D.
The Ohio State University Comprehensive Cancer Center
Columbus, OH

Antonio Wolff, M.D.
Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Kimberly Wright
Advocate in Science
Komen Maryland Affiliate
Towson, MD

Douglas Yee, M.D.
Masonic Cancer Center, University of Minnesota
Minneapolis, MN

Neil Spector, M.D.
Duke University School of Medicine
Durham, NC

Ann Partridge, M.D.
Dana-Farber Cancer Institute
Boston, MA

Patricia Spears
Advocate in Science
Komen NC Triangle to the Coast Affiliate
Morrisville, NC

16 17
“We could give no greater gift to our children than using novel prevention approaches to consign breast cancer to the dustbin of medical history.”

– Komen Chief Scientific Advisor Dr. George Sledge